Trump Executive Order Allocates $50M to Psychedelic Research Boosting Kala Bio’s AI Platform
KALA Bio celebrated President Trump’s Executive Order directing FDA to prioritize psychedelic compound reviews, DEA to ease research restrictions, and allocating $50 million for federal psychedelic therapy research. This policy shift enhances regulatory pathways and commercial momentum for client Red Light Holland’s clinical programs, leveraging KALA’s Researgency.ai platform support.
1. Executive Order Accelerates Psychedelic Research
The Executive Order signed April 18 directs the FDA to prioritize review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research – the most sweeping federal policy shift in decades.
2. Red Light Holland Gains Regulatory Momentum
Expanded patient access and national priority review signals position Red Light Holland’s psychedelic drug development programs to advance clinical and therapeutic trials with materially stronger regulatory and commercial momentum under the new federal framework.
3. KALA Bio’s Researgency.ai Secures Key AI Role
KALA’s proprietary Researgency.ai platform, licensed worldwide from Younet AI, supports Red Light’s clinical planning, protocol optimization, and scenario modeling, reinforcing KALA Bio’s position as the dedicated AI infrastructure partner for global biotech and psychedelic drug development.